ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 182 filers reported holding ASCENDIS PHARMA A/S in Q1 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $2,908,664 | -35.2% | 27,128 | -26.2% | 0.04% | -40.9% |
| Q4 2022 | $4,487,300 | -99.9% | 36,742 | -55.0% | 0.07% | -48.4% |
| Q3 2022 | $8,426,015,000 | +11.6% | 81,600 | +0.5% | 0.13% | +30.6% |
| Q2 2022 | $7,551,141,000 | -17.9% | 81,230 | +3.6% | 0.10% | -7.5% |
| Q1 2022 | $9,200,553,000 | -14.9% | 78,396 | -2.4% | 0.11% | -5.4% |
| Q4 2021 | $10,807,065,000 | -21.2% | 80,332 | -6.7% | 0.11% | -23.8% |
| Q3 2021 | $13,722,681,000 | +42.0% | 86,095 | +17.2% | 0.15% | +51.5% |
| Q2 2021 | $9,661,033,000 | +3.3% | 73,440 | +1.2% | 0.10% | -5.8% |
| Q1 2021 | $9,355,270,000 | -27.6% | 72,589 | -6.4% | 0.10% | -29.9% |
| Q4 2020 | $12,929,952,000 | +4.2% | 77,527 | -3.6% | 0.15% | -12.5% |
| Q3 2020 | $12,413,964,000 | +1.8% | 80,443 | -2.4% | 0.17% | -7.7% |
| Q2 2020 | $12,194,652,000 | +56.9% | 82,452 | +19.4% | 0.18% | +35.8% |
| Q1 2020 | $7,773,693,000 | -32.7% | 69,032 | -16.9% | 0.13% | -10.1% |
| Q4 2019 | $11,552,385,000 | +44.8% | 83,039 | +0.2% | 0.15% | +34.2% |
| Q3 2019 | $7,979,053,000 | +46.1% | 82,839 | -5.0% | 0.11% | +19.4% |
| Q4 2018 | $5,460,574,000 | – | 87,160 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |